- About Us
- Advertise
- Contact Us
- CureToday.com
- CancerNetwork.com
- OncLive.com
- Do Not Sell My Information
- Privacy
- Terms & Conditions
© 2021 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Hematology | Clinical
FDA Breakthrough Therapy Designation Granted to Venetoclax/Azacitidine for Treatment-Naïve MDS
July 21, 2021
The FDA has granted breakthrough therapy designation to the combination of venetoclax and azacitidine for the treatment of adult patients with previously untreated intermediate-, high- and very high-risk myelodysplastic syndromes.
Future Directions in Systemic Treatment of HCC
July 20, 2021
Richard S. Finn, MD concludes the discussion by commenting on areas of unmet need in the care of HCC and emphasizes the potential impact of trials studying treatment combination and sequencing.
Clinical Trials of Lenvatinib Combination Therapy
July 20, 2021
A thought leader in the management of hepatocellular carcinoma provides an overview of several clinical trials of combination therapy with lenvatinib including studies of real-world evidence and potential biomarkers.
Lenvatinib Combination Therapy for Treatment of HCC
July 20, 2021
An expert hematologist-oncologist considers the potential role of combination therapy with lenvatinib for patients with hepatocellular carcinoma.
The REFLECT Study of Lenvatinib for Unresectable HCC
July 20, 2021
A key opinion leader in liver cancer reviews the study design of the REFLECT trial of lenvatinib in patients with HCC and shares key insights into its safety and efficacy data.
Defining Unresectable and Advanced HCC
July 20, 2021
Richard S. Finn, MD defines unresectable or advanced hepatocellular carcinoma by discussing venous invasion, extrahepatic spread, and progression after locoregional treatments.
An Overview of Hepatocellular Carcinoma
July 20, 2021
An expert in hematology-oncology, Richard S. Finn, MD, provides an overview of hepatocellular carcinoma by discussing its prevalence, patient risk factors, and overall prognosis.
First Patient Dosed in LAVA-051 Hematologic Malignancy Trial
July 19, 2021
The first patient has been dosed in the phase 1/2a clinical trial, designed to evaluate LAVA-051- a gamma-delta bispecific gamma-delta T cell engager that activates Vγ9Vδ2 T cells and type 1 natural killer T cells-in those with chronic lymphocytic leukemia, multiple myeloma, and acute myeloid leukemia.
Clinical Trial Matching Service in Hematologic Cancers Mitigates Barriers to Enrollment
July 18, 2021
A national, telephone-based nurse navigator-led service model that aimed to reduce barriers to clinical trial participation among patients with a blood cancer and identified patient demographic and clinical characteristics associated with enrollment was shown to mitigate modifiable barriers to trial enrollment.
Exploring the Use of Orca-T for Patients With Acute and Chronic GVHD
July 16, 2021
Mehrdad Abedi, MD, discusses Orca-T, a high precision cell therapy, for patients with acute and chronic graft-vs-host disease.